The cytokine interleukin-1 (IL-1) is important in many human diseases, and drives a wide range of inflammatory responses in a number of cell types. Biological agents that target IL-1 neutralization have shown efficacy in patients with rheumatoid arthritis. Recently, new classes of compounds that target IL-1 production or processing, or regulatory steps on the IL-1 pathway, are being investigated as new drugs for the management of inflammatory disease. Such compounds will have wide utility in numerous inflammatory conditions.
机构:
Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USAUniv Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USA
Hallegua, DS
Weisman, MH
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USAUniv Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USA
机构:
Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USAUniv Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USA
Hallegua, DS
Weisman, MH
论文数: 0引用数: 0
h-index: 0
机构:
Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USAUniv Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Dept Rheumatol, Los Angeles, CA 90048 USA